Latest launch progress and price comparison of larotinib/larlotinib generic drugs

Larotrectinib As one of the representative drugs of precision medicine, its original drug has a relatively high price due to high research and development costs, long approval period, and it is difficult for ordinary patients to afford it in the long term. Therefore, in many developing countries, the generic drug market is gradually emerging, providing affordable treatment options for more patients with NTRK fusion mutations. The launch of larotrectinib generics not only expands the clinical accessibility of the drug, but also promotes the popularization of molecular targeted therapy for tumors.

Currently, the common generic drugs of larotrectinib on the market are mainly produced by many well-known pharmaceutical companies in Bangladesh and Laos. These include Bangladesh’s Ziskar Pharmaceuticals, Everest Pharmaceuticals, and Yipin International, as well as Laos’ Daxiong Pharmaceuticals, ASEAN Pharmaceuticals, United Pharmaceuticals, and Lucius Pharmaceuticals. Most of these pharmaceutical companies have WHO-GMP or local official certification, and their products have undergone standardized production processes and quality control systems to ensure that the ingredients, bioavailability and efficacy of generic drugs are basically consistent with the original drugs.

Take the Laotian version of larotrectinib as an example, with a specification of 100 mg × 56 capsules. The current market price is approximately RMB 1,000 to RMB 1,900 (depending on the channel, batch and exchange rate fluctuations), which is much lower than the original drug Tabrecta (a single box in the US market can be sold for as high as RMB 30,000 to RMB 50,000). Therefore, generic drugs have significantly reduced the cost of treatment and have extremely high economic value, especially for patients who require long-term medication or are not covered by medical insurance.

At present, larotrectinib has been officially approved for marketing in mainland China and has been included in my country's medical insurance. Because the price is relatively expensive, patients can obtain generic drugs through overseas medical treatment, intermediary drug purchase, or cross-border direct purchase. Although generic drugs have good clinical substitution, it is still recommended to purchase them from formal channels and use them under guidance, and at the same time cooperate with genetic testing to ensure medication use.

Reference materials:https://www.vitrakvi.com/